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Abstract
Background and Aim: Little is known about the risk of serious infection when combining anti-
tumour necrosis factor [TNF] therapy for refractory inflammatory bowel disease [IBD] with 
immunosuppression after liver transplantation [LT]. Our aim was to investigate the infection risk in 
this patient group by systematic review and meta-analysis of the available data.
Methods: A search was conducted for full papers and conference proceedings through September 
2015, regarding liver transplant recipients and anti-TNF therapy. All studies were appraised using 
the adapted Newcastle-Ottawa Scale [NOS]. Two reviewers independently extracted patient data 
[age, duration of follow-up, number of all infections, number of serious infections, time since 
transplant]. As an additional control population, primary sclerosing cholangitis [PSC]-IBD patients 
from the Leiden University Medical Center [LUMC] LT cohort were used. Poisson regression was 
used to compare serious infections (according to International Conference on Harmonisation [ICH] 
definition) per patien-year follow-up between the anti-TNF and control groups.
Results: In all 465 articles and abstracts were identified, of which eight were included. These 
contained 53 post-LT patients on anti-TNF therapy and 23 post-LT patients not exposed to anti-
TNF therapy. From the LUMC LT-cohort, 41 PSC patients with PSC-IBD not exposed to anti-TNF 
therapy were included as control population. The infection rate for TNF-exposed patients was 0.168 
serious infections per patient year, compared with 0.149 in the control patients (rate ratio 1.12 [95% 
confidence interval: 0.233–5.404, P = 0.886]. When correcting for time since transplant, the infection 
rate was 0.194 in the TNF-exposed vs 0.115 in the non-exposed [p = 0.219].
Conclusions: No significant increase in the rate of serious infection was observed in LT recipients 
with PSC-IBD during exposure to anti-TNF therapy.
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1. Introduction
Primary sclerosing cholangitis [PSC] is an inflammatory and fibros-
ing liver disease involving the intra- and extrahepatic biliary tract. 
As no pharmaceutical or other disease-modifying therapeutic agent 
is available, a substantial portion of the patients eventually progress 
to end-stage liver disease or develop cholangiocarcinoma, requiring 
liver transplantation [LT].1
Nearly 70% of PSC patients have concurrent inflammatory 
bowel disease [IBD]3 and, after liver transplantation, IBD activity 
increases in one-third of patients.4 This group poses a difficulty for 
the treating physician when mucosal healing is not achieved with 
conventional anti-inflammatory drugs. Anti-TNF therapy has been 
shown to be effective in both inducing and maintaining remission 
in IBD patients with refractory disease,5 but was associated with an 
increase in the incidence of [serious] infections in some studies.6 In 
liver transplant recipients, infections are important cause of mortal-
ity after LT.7,8 Data on the risk of serious infection when combining 
anti-TNF therapy for IBD treatment with immunosuppression for 
prevention of rejection are scarce. To assess the safety of anti-TNF 
therapy in these patients, we performed a systematic review and 
meta-analysis in order to calculate and compare the serious infec-
tion rate in liver transplant recipients with and without anti-TNF 
exposure.
2. Methods
This study was conducted in accordance with the PRISMA 
statement.9
2.1. Search strategy
A systematic literature search was conducted of the following data-
bases: PubMed, Embase, COCHRANE and Web of Science, for full 
papers, letters and abstracts. The literature search was performed by 
two authors [MWvM, PWJM] and a library information specialist. 
All entries were searched up to January 2017. The complete search 
strategy is available in Supplementary Data, available at ECCO-JCC 
online.
2.2. Study selection
Two authors independently reviewed the titles and abstracts of the 
identified papers, letters, and abstracts, and selected them for detailed 
assessment. These full articles, letters and abstracts were reviewed 
to select studies eligible for our final analysis. Studies were consid-
ered eligible if they met the following criteria: [I] the studies had to 
report on the incidence of serious infections in post-transplantation 
patients under treatment with any anti-TNF therapy for IBD; [II] 
the intervention of interest was concurrent anti-TNF-therapy and 
immunosuppression against transplant rejection, but concurrent 
use of other IBD medication was permitted; [III] studies could be of 
prospective and retrospective nature; [IV] studies without a control 
group were included in our selection, to maximize data quantity; 
[V] studies could not contain duplicate data already published; [VI] 
studies were written in English; and [VII] studies contained all data 
needed for analysis or data were provided by an author [Combes, 
Modiri, Pavlidis].As an additional source of control patient data, 
patients from the Leiden University Medical Center [LUMC] liver 
transplantation cohort were used. Eligibility criteria for this control 
Published studies (Pubmed, Embase, Cochrane, Web of Science)
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Figure 1. Flow chart of search strategy.
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group were: liver transplant in history; alive 6 months post-trans-
plant; IBD diagnosis; and no current or previous anti-TNF-therapy.
2.3. Data extraction
Two authors independently extracted the following patient and 
control data from each paper: author, year, study type, number of 
patients, patient age, number and type of infections, follow-up time, 
and time since transplant, using standard extraction forms. Serious 
infections were defined according to the serious adverse event defini-
tion of the International Conference on Harmonisation [ICH] guide-
lines for clinical safety data management.10
If data was missing from a paper, the authors were contacted 
to obtain this missing data. The same patient data was extracted 
from patient records for the LUMC control group, after consent 
from the Leiden University medical Center [LUMC] ethics commit-
tee [MEC number G16-004]. Follow-up of LUMC patients started 
6 months after [re-]transplant, to correct for the transplantation 
surgery-related increased infection rate, and ended at death or 
study end.
2.4. Quality assessment
Two authors independently assessed the risk of bias in all eligible 
studies. All studies were appraised using the adapted Newcastle-
Ottawa Scale [NOS], which contains nine criteria for cohort 
studies and is adapted to six criteria for case series and case 
reports.11
To assess the risk of outcome-reporting bias, all studies were 
scanned for statements about inclusion of all patients within our 
inclusion criteria as opposed to statements of patient selection.
2.5. Data synthesis and analysis
The patient data waereanalysed using Poisson regression models, 
with a scale parameter to allow for heterogeneity between stud-
ies and with the natural logarithm of the total number of years of 
follow-up as offset variable, to allow for the between-studies dif-
ferences in total time at risk. This modelling applies inverse vari-
ance weighting and calculates a combined serious infection rate per 
patient-year [PY] for the anti-TNF group and the control group, 
resulting in a rate ratio of the two serious infection rates.
Before the analysis, possible confounders were considered. Time 
between transplant and the start of follow-up, and patient age, were 
considered factors that could potentially affect serious infection rate 
and therefore cause confounding in our analysis. To solve this, addi-
tional analyses were performed with these factors as covariables. 
Data were analysed using SPSS v23.
3. Results
Figure 1 describes the search strategy. Initially 465 articles and con-
ference proceedings were found, of which 28 citations were deemed 
potentially relevant. Finally, eight papers were included in the analy-
sis. Both reviewers agreed on the final selection of these studies.
Table 1. Data of liver transplant recipients on anti-TNF treatment, extracted from papers included in the analysis.
Authors N Mean age [years] 
at start of  
follow-up
Number of serious 







Study type NOS checklist






0.9 Case series 5/6




1.5 Case series 5/6





1.5 Case series 5/6
Combes et al.19 18 37.2 [24–51.9] 7 [2 x C. diff., 1 x 
E. faecalis septicae-
mia, CMV, digestive 
cryptosporidiosis, 















2.2 Letter, case 
series
5/6
Modiri15 9 39.3 3 [C. diff., CMV, 
bactaeremia]
3.86 Cohort study, 
abstract
7/9
Karolina21 1 25 0 1 tacrolimus
1 azathioprine
3.16 Case report 4/6
Lal22 1 29 0 1 tacrolimus 0.55 Case report 4/6
Total 51 15 2.2
NOS, Newcastle-Ottawa Scale; C. diff., Clostridium difficile colitis; EBV, Epstein-Barr virus; CMV, cytomegalovirus; HEV, hepatitis E virus infection.
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Table 1 shows the total NOS score for each study. None of the 
studies scored less than 75% of the NOS quality criteria. None of 
studies received a point on ‘demonstration that outcome of interest 
was not present at start of study’, as none reported whether patients 
had infection at the start of follow-up. It however seems unlikely 
that anti-TNF therapy was started during a serious infection.
From these studies, data were extracted on 53 patients on anti-
TNF therapy and 23 control patients not on anti-TNF therapy. Table 1 
shows the patient safety data collected for all patients on anti-TNF 
therapy. No mortalities were reported in any of the study patients.
We identified 41 patients in the LUMC liver transplant cohort 
who had IBD and underwent LT. Table 2 shows the characteristics 
for these included patients. Table 3 shows all control patient data.
3.1. Meta-analysis results
As shown in Table  4, the overall infection rate for TNF-exposed 
patients was 0.168 serious infections per patient-year, which was 
similar to the 0.149 per year in the control patients [p = 0. 886].
Age at time of transplant was not associated with the rate ratio 
for serious infections, whereas the time since transplantation was. 
Although correcting for time since transplant increase, the difference 
in infection rates between the anti-TNF-group and the control group 
[0.194 vs 0.115 serious infections per patient-year] the rate ratio 
remained non-significant [1.70, p = 0.219].
3.2. Sensitivity analysis
We excluded the two case reports, but this did not alter the results. 
After exclusion of the case reports, time since transplant still influ-
enced [p  < 0.001] the infection rates in these groups. The serious 
infection rate did not differ between groups [p = 0.146].
4. Discussion
This meta-analysis investigated the safety of anti-TNF therapy in 
liver transplant recipients with IBD. As no randomised controlled 
trials [RCTs] were available, a cohort study, case series, and case 
Table 3. Control patient data from LUMC cohort and studies.
N Mean age [years]  
at start of follow-up
Number of serious  
infections
Type of infection Patient-years follow-up
LUMC cohort 41 45.13 69 5 x viral gastroenteritis
9 x [recurring] C=cholangitis
2 x neutropenic fever
12 x pneumonia
2 x spontaneous peritonitis
5 x bacterial gastroenteritis
6 x bacteraemia
7 x CMV infection
4 x sepsis unknown origin
2 x EBV infection
4 x complicated urinary tract infection
1 x Clostridium enterocolitis
1 x spondylodiscitis with abscess
1 x sinusitis
2 x fever unknown origin
1 x cellulitis
1 x prostatitis
1 x influenza hospitalisation
1 x perianal abscess
1 x rotavirus hospitalisation
1 x line sepsis
264.3






LUMC, Leiden University Medical Center; EBV, Epstein-Barr virus; CMV, cytomegalovirus; MRSA, methicillin-resistant Staphylococcus aureus.
Table 2. Patient characteristics, LUMC cohort [41 patients].
N
Mean age in years [range] 45 [18–68]
Gender [% male] 70.7
IBD type [%]
 Ulcerative colitis 78.0
 Crohn’s disease 19.5
 Unspecified IBD 2.4%
Indications for LT [%]
 PSC 87.8
 PSC & AIH 7.3
 Cholangiocarcinoma 2.4
 Hepatocellular carcinoma 2.4
Re-graft 17.1




 Liver failure 2.4
 Other 7.2
LUMC, Leiden University Medical Center; IBD, inflammatory bowel dis-
ease; PSC, primary sclerosing cholangitis; AIH, auto immune hepatitis.
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reports were included. Only one cohort study was identified, so data 
from the Leiden University Medical Centre liver transplant cohort 
were used as additional control population.
No difference in the serious infection rate between liver trans-
plant recipients with and without anti-TNF therapy was found. 
However, as the confidence intervals are wide, this does not fully 
rule out any clinically significant increase in risk due to addition of 
anti-TNF therapy. However, in the over 100 patient-years of follow-
up during TNF-exposure analysed in this study, no important safety 
signal was detected. A  recent meta-analysis on the safety of anti-
TNF therapy in non-transplant IBD patients found no increase in 
occurrence of serious infections,12 although other studies found an 
increase in serious infections after anti-TNF exposure.6
The serious infection rate found in our study is substantially higher 
than the number found in the treat registry of serious infections while 
using infliximab [15/100 patient-years vs 2.4/100 patient-years]. This 
is not surprising: in LT recipients, infections are a substantial threat 
to patient survival. For instance, Daniel et al. recently described that 
18% of LT recipient mortality is due to infections.13 Use of anti-TNF 
therapy does not seem to further increase this risk.
In a study not included in this meta-analysis due to missing data, 
five patients after LT are treated with infliximab, two of whom 
develop infectious complications and two develop a post trans-
plant lymphoproliferative disease [PTLD].14 No clinical benefit was 
observed in any patient treated with anti-TNF.
The primary limitations of the current analysis are its size and the 
study types used in the analysis. No RCT and only one cohort study 
was included. Larger cohort studies would allow for correcting for 
differences between hospitals or regions in treatment or admission. 
The only cohort study15 found no increased risk for infections in the 
anti-TNF exposed group. In summary, our results suggest that anti-
TNF-treatment in combination with LT-associated immunosuppres-
sion does not increase the serious infection rate. To further confirm 
the safety of anti-TNF therapy in post-transplant patients, additional 
patient data are needed.
Conflict of Interest
None of the authors had a conflict of interest.
Acknowledgments
The authors would like to thank Jan Schoones, library information specialist, 
for the search strategy.
Author Contributions
MWvM performed the data collection, literature search,d initial statisti-
cal analysis, and writing of the paper; BH, AEvdM, RA, GPP, and DS were 
involved in interpreting the data; and BvH and AI contributed substantially 
to study design and interpretation of the data. TS contributed to study design, 
data interpretation, and performing and designing statistical analysis. PWJM 
contributed to data collection and literature search, study design, interpreting 
data and data analysis, writing of the paper, and supervision of the project.
Supplementary Data
Supplementary data are available at ECCO-JCC online.
References
 1. Boonstra K, Beuers U, Ponsioen CY. Epidemiology of primary sclerosing 
cholangitis and primary biliary cirrhosis: a systematic review. J Hepatol 
2012;56:1181–8.
 2. Adam R, Karam V, Delvart V, et al.; all contributing centers [www.eltr.org]; 
European Liver and Intestine Transplant Association [ELITA]. Evolution of 
indications and results of liver transplantation in Europe. A report from the 
European Liver Transplant Registry [ELTR]. J Hepatol 2012;57:675–88.
 3. Loftus EV Jr, Sandborn WJ, Lindor KD, Larusso NF. Interactions between 
chronic liver disease and inflammatory bowel disease. Inflamm Bowel Dis 
1997;3:288–302.
 4. Singh S, Loftus EV Jr, Talwalkar JA. Inflammatory bowel disease after 
liver transplantation for primary sclerosing cholangitis. Am J Gastroen-
terol 2013;108:1417–25.
 5. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and 
maintenance therapy for ulcerative colitis. N Engl J Med 2005;353:2462–76.
 6. Singh JA, Wells GA, Christensen R, et al. Adverse effects of biologics: a 
network meta-analysis and Cochrane overview. Cochrane Database Syst 
Rev 2011;16:CD008794.
 7. van Hoek B, de Rooij BJ, Verspaget HW. Risk factors for infection after 
liver transplantation. Best Pract Res Clin Gastroenterol 2012;26:61–72.
 8. Daniel KE, Eickhoff J, Lucey MR. Why do patients die after a liver trans-
plantation? Clin Transplant 2017;31. doi: 10.1111/ctr.12906. [Epub Feb 
6, 2017.]
 9. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for report-
ing systematic reviews and meta-analyses of studies that evaluate health-
care interventions: explanation and elaboration. BMJ 2009;339:b2700.
 10. International Conference on Harmonisation of Technical Requirements 
for Registration of Pharmaceuticals for Human Use. ICH Expert Working 
Group. ICH Harmonised Tripartite Guideline. Clinical Safety Data Man-
agement: Definitions and Standards for Expedited Reporting. E2A, 1994. 
https://wwwichorg/fileadmin/Public_Web_Site/ICH_Products/Guidelines/
Efficacy/E2A/Step4/E2A_Guidelinepdf. Accessed January 10, 2017.
 11. Wells GA Shea B, O’Connell D, et al. The Newcastle-Ottawa Scale [NOS] 
for Assessing the Quality of Nonrandomised Studies in Meta-Analyses. 
2011.http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. 
Accessed January 10, 2017.
 12. Bonovas S, Fiorino G, Allocca M, et  al. Biologic therapies and risk of 
infection and malignancy in patients with inflammatory bowel disease: a 
systematic review and network meta-analysis. Clin Gastroenterol Hepatol 
2016;14:1385–97.e10.
 13. Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects 
and established and evolving therapies. Lancet 2007;369:1641–57.
 14. Parekh P, Segovia M, Kaur N. Tumor-necrosis-factor-α antagonist therapy 
for inflammatory bowel disease after liver transplantation. ATC abstracts. 
Am J Transplant 2016;16 [Suppl 3]:2016.
 15. Modiri AN, Naik AS, Rizvi S, Zadvornova Y, Stein D. Inflammatory 
bowel disease patients with solid organ transplants who require anti-TNF 
Table 4. Meta-analysis: serious infection rates and rate ratio for liver transplant recipients exposed and non-exposed to anti- TNF therapy.
Anti-TNFexposed [95% CI] Non-exposed [95% CI] Rate ratio p-Value Correction factor used p-Value
0.168 [0.040–0.710] 0.149 [0.080–0.278] 1.12 [0.233–5.404] 0.886 None NA
0.127 [0.021–7.67] 0.099 [0.030–0.331] 1.282 [0.257–6.393] 0.762 Age at transplantation 0.423
0.194 [0.094–0.413] 0.115 [0.076–0.172] 1.70 [0.730–3.934] 0.219 Time since transplantation p < 0.001
TNF, tumour necrosis factor; CI, confidence interval; NA, not available.
Downloaded from https://academic.oup.com/ecco-jcc/article-abstract/11/9/1146/3800485
by Leiden University / LUMC user
on 13 February 2018
Anti-TNF Treatment in Liver Transplant Recipients 1151
therapy are not at increased risk of serious infections. Gastroenterology 
2015;148:S61.
 16. Mohabbat AB, Sandborn WJ, Loftus EV Jr, Wiesner RH, Bruining DH. 
Anti-tumour necrosis factor treatment of inflammatory bowel disease in 
liver transplant recipients. Aliment Pharmacol Ther 2012;36:569–74.
 17. Sandhu A, Alameel T, Dale CH, Levstik M, Chande N. The safety and effi-
cacy of antitumour necrosis factor-alpha therapy for inflammatory bowel 
disease in patients post liver transplantation: a case series. Aliment Phar-
macol Ther 2012;36:159–65.
 18. Indriolo A, Fagiuoli S, Pasulo L, Fiorino G, Danese S, Ravelli P. Letter: inf-
liximab therapy in inflammatory bowel disease patients after liver trans-
plantation. Aliment Pharmacol Ther 2013;37:840–2.
 19. Combes R, Altwegg R, Laharie D, et al. Efficacy and safety of anti-TNF 
therapy for inflammatory bowel disease [IBD] in liver transplant recipi-
ents for primary sclerosing cholangitis [PSC]: a multicenter experience. J 
Crohns Colitis 2015;9:S40.
 20. Pavlidis P, Potts J, Barnabas A, et al. Anti-tumour necrosis alpha treatment 
in primary sclerosing cholangitis associated inflammatory bowel disease 
post liver transplantation. Liver transpl 2015; 21:1455.
 21. Karolina S, Chetan M. A unique case of biologic therapy for IBD 
post liver transplant. Inflammatory bowel diseases. In: Advances 
in Inflammatory Bowel Diseases. Crohn’s and Colitis Founda-
tion’s National Clinical and Research Conference: December 2014; 
Orlando, FL.
 22. Lal S, Steinhart AH. Infliximab for ulcerative colitis following liver trans-
plantation. Eur J Gastroenterol Hepatol 2007;19:277–80.
Downloaded from https://academic.oup.com/ecco-jcc/article-abstract/11/9/1146/3800485
by Leiden University / LUMC user
on 13 February 2018
